A：The company had 16 blockbuster medicines in 2025, with 17 growing at double digits. The expectation is to reach 25 blockbusters by 2025, which is in line with the previously announced $80 billion target.

A：The company achieved a 8% growth in total revenue and a 10% growth in product revenue in 2025, driven by continued global demand for innovative medicines.

A：The company's R&D teams delivered with 16 positive phase 3 trial results in 2025, which have a combined sales potential of $10 billion. They also secured 43 approvals for medicines across major regions.

A：The company's portfolio strength is evident with the diversification across product areas and geographies. Growth was across various therapy areas, with oncology growing 17% and cardiovascular diseases 12%. Strong growth was also seen in the US (10%), Europe, and notably in emerging markets outside of China, which grew 22%.

A：The company has more than 100 phase 3 trials ongoing, with 20 phase 3 readouts expected this year. If positive, these could drive an additional $10 billion in peak revenue. The pipeline is anticipated to deliver similarly high numbers in 2027, with most of the upcoming readouts needing to be positive.

A：The company has two products in phase 3 for weight management and cardiovascular risk factors. They announced the progression of all GLP-1 receptor agonists to phase 3, and are planning to invest in new products that shape the future of weight management, such as improved convenience and longer duration of action for injectables.

A：The company managed core R&D expenses to increase by 12% due to a growing pipeline, while SGA expenses increased by only 3% reflecting cost discipline. Core operating profit grew by 9%, and core EPS increased by 11%, in line with the company's guidance.

A：The company has a progressive dividend policy and declared a second-term dividend of $2.17 per share, resulting in a full-year 2025 dividend of $3.20 per share. They intend to increase the annual declared dividend to $3.30 per share.

A：For 2026, the company anticipates total revenue to grow by a mid to high single-digit percentage, despite known headwinds such as VBP in China and loss of exclusivity for certain products. They expect broadly flat to slightly higher core gross margin, a core tax rate between 18 and 22%, and core EPS growth of low double digits at constant exchange rates.

A：SGNA as a percentage of total revenue has continued to decline over recent years, reflecting a disciplined approach to efficiency and operating leverage.

A：AstraZeneca anticipates a step up in core net finance expense for 2026, driven by higher lease expenses and lower interest income.

A：In 2025, oncology delivered total revenues of $25.6 billion, an increase of 14% on the prior year, or 17%, excluding the 2024 sales milestone.

A：For the fourth quarter, total revenues exceeded $7 billion for the first time, up 20% on the year, with key medicines demonstrating double-digit growth across regions.

A：Key catalysts for 2026 include the US approval for early gastric cancer treatment, new indications for Infinity in various cancers, and continued expansion of its hematology portfolio through combination approaches.

A：AstraZeneca is focused on bringing therapies to more patients globally, including in settings beyond breast cancer such as lung cancer.

A：The imminent launch expected for calquence in the US is of the Amplify Finite therapy regimen, which is expected to be an important driver of growth.

A：Anticipated readouts for 2026 include those for Dara in HR positive breast cancer and E G R mutated lung cancer, as well as trials evaluating Dara in the first line lung cancer setting and setting new standards for second line treatment.

A：The trials mentioned are significant in that they aim to bring transformative therapies to patients by establishing roles for combinations in local regional settings for diseases like hepatocellular carcinoma and improving outcomes for muscle invasive bladder cancer.

A：The biopharmaceuticals medicines delivered strong performance in 2025 with total revenue up 5% to $23 billion and biologic medicines gaining share among severe asthma patients.

A：Fas Ra's positive momentum is expected to continue in 2026, with growth in emerging markets accelerating following inclusion in China's national reimbursement drug list, and the medicine has made rapid market share gains in severe asthma.

A：Luma's strong growth is expected to continue into 2026, with demand growth anticipated in Europe and emerging markets, and fixed dose combinations of depala flows have the potential to unlock new waves of growth.

A：Baxters Tad represents a major potential growth driver for the biopharmaceuticals business, with peak revenues expected to exceed $5 billion.

A：The clinical trial with wanua aims to address the upstream driver of amyloid fibro formation in ATTR cardiomyopathy. The trial's primary endpoint is a composite of cardiovascular mortality and recurrent cardiovascular clinical events, capturing clinically meaningful outcomes.

A：The phase 3 program for the differentiated Il 33 biologic, Tozer auma, in COPD aims to redefine the management of the complex, heterogeneous, and progressive disease. It focuses on the reduction in the annualized rate of moderate to severe COPD exacerbations, with evaluations across a broad COPD population and various dosing regimens.

A：The once daily oral GLP 1 receptor agonist aleo glironia (known as Azd 5004) has met its primary endpoints in both the Vista and solstice phase 2 b trials for obesity or type 2 diabetes. It is progressing into phase 3 development this year.

A：The company's weight management portfolio seeks to address obesity and interconnected conditions through a diversified pipeline that explores innovative novel combinations. It includes a selective amylin receptor agonist and a dual GLP 1 glucagon receptor agonist, both advancing toward first phase 2 data.

A：The rare disease portfolio delivered total revenue of $9.1 billion in 2020, up 4% over the previous year. It grew due to patient demand, cost indicators, and continued global expansion. With 5 years post-acquisition of Alexion, there is a report of low double-digit compounded annual growth at constant exchange rates. The reach expanded from 20 to over 75 countries with the use of AstraZeneca's footprint.

A：In 2026, Alto Me is expected to continue growing with knowledge, indication, and market expansions, including new indications like HT TM AI and CSA Aki. Sales are anticipated to be above $5 billion with contributions from existing and new indications. Key drivers for growth include high-level results in Egan, plans for accelerated approval in major markets, and data from adult patients with Htt TMA.

A：The Antibody-based Deion portfolio is advancing with a focus on the two most prevalent forms of amyloids, trans 18 and light chain. The most advanced pipeline candidate, on selei Ma, showed a highly meaningful improvement in both all-cause mortality and cardiovascular outcomes in a subgroup of patients with kappa light chain amyloidosis.

A：The collaboration with Nuri MN for the treatment of ATTR cardiomyopathy is in phase 3 with the De trial fully enrolling ahead of plan, with more than 1000 patients recruited. Plans include initiating a phase 2 B of silence renewal with a deeper kramme, aiming for a new standard of care for patients with ATTR cardiomyopathy.

A：The potential of the collaborations and管线 beyond 2030 in oncology hinges on continued strong performance, risk adjustment, and the integration of multiple transformation technology to meet the 80 billion ambition by 2030 and beyond.

A：The outlook for China in 2026 includes challenges such as post-VVP headwinds for roxadustat. However, there is confidence in a brand recovery, driven by strong brand perception and loyalty, particularly in the retail channel. New launches are expected to drive growth with successful inclusions of faser through cup and kalpin tablets starting from January 1st this year. Despite profitability being lower than the group, the view considers the large volume, unmet need, and opportunity in China against slightly lower prices globally.

A：The goal of the foundation model work with Tempest and Pathos is to create the largest multimodal foundation model for oncology that integrates various types of data such as unstructured patient records, lab data, genomics data, and imaging data. This integration is expected to help reduce uncertainty in the design and prediction of outcomes for phase 3 trials, particularly when dealing with new biomarkers where historical literature data may be limited. By using these data sets, it is hoped that the model can better identify patient populations with more complicated biology, and improve the understanding and prediction of trial outcomes.

A：The highlighted products in the biopharma company's portfolio that are expected to drive growth include Emerald 3, which is considered a blockbuster plus opportunity in HCC and builds off a program with success within finzi. The a-z share of Dato across avanzar 0 7 is described as a multi-blockbuster opportunity. Serena 4 is noted for its multi-blockbuster potential. Additionally, P 9, if it yields positive results, could build off the company's Pacific leadership with minimal competition.

A：The JP Morgan report suggests that oral Pcsk 9 has high potential, with the potential to be a $5 billion plus product. Other significant potential products mentioned include Baxter stat, with potential sales between 3 and 5 billion, and a product hitting the target product profile (TPP) in the COPD space, which is believed to have multibillion-dollar potential.

A：The implications of the trial result on the design of the Serena 4 trial are related to patient population selection, as it aims to enrich for endocrine-sensitive components of the first-line setting. The study design focuses on recruiting patients with recurrence from early-stage disease after at least two years of standard adjuvant therapy, which is expected to increase the effect size. The prevention of the emergence of ESL 1 mutations also underpins the confidence in the trial. Regarding commerciality, the successful design and outcome of the trial could significantly impact the company's commercial strategy and success in the market.

A：The basis of confidence for the success of the Serena 4 trial is rooted in the design, which enriches for endocrine-sensitive components by recruiting patients with recurrence from early-stage disease after specific therapy periods. The mechanism of action for the study involves full antagonism and inhibition of estrogen receptor, along with degradation activities, which are expected to have activity not just in the e.r. one mutant but also in the endocrine-sensitive ESL wild type. This understanding of the mechanism of action and patient selection is expected to demonstrate efficacy in the endocrine-sensitive population and potentially prevent the development of specific mutations, which increases the confidence in the trial's success.

A：The unique aspect of the Electrip Phase 3 study is that it is the only study that will assess the efficacy of the product in a weight management context in combination with other cardiovascular agents. The confidence in moving the study to Phase 3 is indicative of the product's efficacy, which is believed to be competitive or better than the competition, even without combination therapy. The monotherapy itself is expected to demonstrate efficacy, with the potential for additional benefits when combined with other agents.

A：The potential market size for the zmit A's alpha trials is based on a 3 to 5 billion opportunity. There are three different trials, and their success or otherwise would alter the projected opportunity. If any of the trials are less successful than anticipated, it could reduce the overall market potential. However, if all trials are successful, it could potentially provide a product with a greater value than currently estimated. The level of success across these trials is crucial in determining the extent of the market opportunity.

A：The differentiation of toza aimmat lies in its highly specialized Il 33 biologic, which is capable of impacting both the St two pathway and the EGFR pathway, thereby influencing signaling downstream that is crucial in COPD. The molecule's ability to inhibit mucus production and epithelial remodeling is particularly important for COPD treatment, as it addresses the mucus production that drives exacerbations. Toza aimmat's broad study design, which examines efficacy across current and former smokers and various levels of eosinophils, allows for application to the broadest possible patient population, further underpinning the confidence in the program.

A：The expectations for Calquence growth are beating consensus estimates, with a forecast of 10% or more in 2026 and 2025. The potential gating events for unlocking further growth include US approval anticipated after European approval has been achieved, and the differentiation of Calquence's profile to compete against existing therapies. The introduction of the first Bcl2 and Btk combination therapy in the US represents a new approach to treating CLL and could be significant for Calquence's growth, particularly in the US market, which is the largest portion of global sales.

A：The upcoming study on cardiac arrhythmias is significant as it is the largest ever designed for this condition. It is intended to differentiate patient outcomes based on baseline medication usage, which is crucial for shaping treatment guidelines and the clinical approach to patients with cardiac arrhythmias. AstraZeneca is confident in the study's design, which will allow specific analysis to inform these guidelines and potentially alter the standard of care for arrhythmias.

A：AstraZeneca plans to expand its reach into new markets by continuing to develop and advance research in obesity and related conditions. They believe in the potential of combination therapies to reduce cardiovascular risks for obese and overweight patients. They are focusing on quality aspects of weight loss, such as preserving lean muscle mass and targeting visceral fat. AstraZeneca is well-equipped with research, development capabilities, and recent partnership deals to enter the long-acting medicines market, aiming to address the obesity epidemic and improve patient outcomes.

A：Growth drivers for AstraZeneca's biopharma business outside of oncology in 2026 include the respiratory and immunology portfolio, which has shown significant growth and is expected to continue with products like BR3 and asthma. Additionally, the approval of Sotagliflozin (Baxter stat) is anticipated to contribute to growth despite initial lower sales due to market dominance. Other factors include continued growth of existing products and the potential for new therapies to be launched.

A：AstraZeneca's strategy for capital allocation involves focusing on organic growth and investing in earlier-stage assets to create value, without immediately requiring products to be profitable. They aim to maintain discipline and avoid overpaying for assets. Beyond 2030, AstraZeneca has substantial firepower and capacity to deploy acquisitions and is confident in its ability to create value for shareholders through acquisitions. The company is well-positioned with a broad portfolio and aims to absorb assets into their P&L while focusing on key priorities.

A：Subcutaneous formulations offer convenience to patients and are an area of investment for AstraZeneca across their immuno-oncology portfolio, including bispecifics, and their ADC portfolio. Subcutaneous formulations are also possible for certain doses within AstraZeneca's T cell engage portfolio. This is an emerging trend across biologics and is expected to grow within the company's portfolio.

A：The cardiotoxicity study is the largest ever conducted in this setting, balancing naive and defamatory patients. The trial allows for a stabilizer drop-in, addressing an unmet medical need. Positive results are expected to be very informative for the clinical community and may impact treatment guidelines by demonstrating the additive benefit of a stabilizer on top of standard of care. AstraZeneca is confident that the study will provide landmark data on overall benefit and demonstrate the efficacy of the approach.

A：AstraZeneca views its competitive advantage as enhanced by its presence in China, where it has two R&D centers and a strong reputation. They aim to collaborate and compete with Chinese companies to learn and integrate innovative practices. AstraZeneca's position has been solidified by successful partnerships and reasonable pricing in deal-making. Despite increasing competition and higher costs, AstraZeneca believes in the value of maintaining a presence in China to leverage local R&D and partnership opportunities.